Abridged Sutent Study, Afinitor Data Questioned Before ODAC
Assuming an agreement between the House and the Senate halts a government shutdown, the FDA's Oncologic Drugs Advisory Committee is slated to meet Tuesday to review Pfizer Inc.'s Sutent (sunitinib) and Novartis AG's Afinitor, both of which are seeking expanded approval for pancreatic neuroendocrine tumors (pNET).
